Ena Respiratory

About:

Ena Respiratory researches and develops solutions to transform the treatment and prevention of respiratory infections.

Website: https://enarespiratory.com/

Twitter/X: innavac

Top Investors: AustralianSuper, U.S. Department of Defense, Hostplus, Brandon Capital, Minderoo Foundation

Description:

Ena Respiratory is a biotechnology company seeking to transform the treatment and prevention of respiratory infections and the effectiveness of vaccines. Ena Respiratory novel, synthetic Toll-like receptor 2 (TLR2) receptor agonists have been shown to activate the innate immune system in the respiratory tract and prevent viral and bacterial dissemination to the lungs.

Total Funding Amount:

$41.5M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Melbourne, Victoria, Australia

Founded Date:

2014-01-01

Contact Email:

info(AT)innavac.com

Founders:

Christophe Demaison

Number of Employees:

11-50

Last Funding Date:

2024-05-07

IPO Status:

Private

Industries:

© 2025 bioDAO.ai